Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q3 2024 Earnings Conference
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q3 2024 Earnings Conference
Administrative expenses decreased by 11% due to reduced general and administrative expenses and professional fees.The following is a summary of the Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript:
以下是Theralase Technologies Inc. (TLTFF) 2024年第三季度业绩会记录的摘要：
Financial Performance:
财务表现：
Theralase Technologies Inc. reported a revenue decrease for the nine-month period of 2024, totaling CAD622,984, which is a 12% decrease compared to the previous year.
The gross margin percentage has decreased year-over-year to 47% due to increased material costs.
Administrative expenses decreased by 11% due to reduced general and administrative expenses and professional fees.
There was a 7% year-over-year reduction in net loss for 2024, with the drug division representing 84% of this loss.
Theralase Technologies Inc.报告称2024年前九个月的营业收入下降，总计622,984加元，同比下降12%。
毛利率百分比因材料成本上升而同比下降至47%。
由于一般行政费用和专业费用的减少，管理费用下降了11%。
2024年的净亏损同比减少了7%，其中药物部门占此亏损的84%。
Business Progress:
业务进展：
Theralase is focusing on expanding enrollment in their Phase II bladder cancer study and expects to add up to five new clinical study sites in late 2024 to early 2025.
The company has also initiated preparations to commence Phase I clinical studies for brain, lung, and blood-based cancers in 2025.
Plans for a topical ointment for herpes simplex lesions and a vaccine for avian influenza are underway.
Theralase正专注于扩大其第二期膀胱癌研究的入组，并预计在2024年底至2025年初新增最多五个临床研究地点。
该公司还已开始为2025年启动脑癌、肺癌和血癌的第一阶段临床研究做准备。
针对单纯疱疹损伤的外用药膏和禽流感疫苗的计划正在进行中。
Opportunities:
机会：
Theralase is leveraging data from Phase II bladder cancer clinical studies for potential FDA and Health Canada regulatory marketing approval.
The company aims for strategic partnership opportunities after the potential approval to aid in commercializing their next standard-of-care treatment for bladder cancer.
Potential opportunities for expanding into treatments for brain cancer, lung cancer, and blood cancers leveraging the growth in global markets for these diseases.
Theralase正利用第二阶段膀胱癌临床研究的数据，争取FDA和加拿大卫生部的监管市场批准。
该公司目标是在潜在批准后寻求战略合作机会，以帮助商业化其下一款膀胱癌标准护理治疗。
由于全球市场对这些疾病的增长，拓展到脑癌、肺癌和血癌治疗的潜在机会。
Risks:
风险：
Theralase anticipates a need for significant funding to complete its ongoing and planned clinical studies, with an estimated cost of CAD15 million to CAD30 million for the Phase II bladder cancer clinical study alone.
Regulatory risks related to obtaining necessary approvals from Health Canada and the FDA for their products are also present.
Theralase预计需要大量资金来完成其正在进行和计划中的临床研究，第二阶段膀胱癌临床研究的估计费用为1500万加元至3000万加元。
获得加拿大卫生部和FDA对其产品所需批准的监管风险也存在。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。